All Articles

Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them

TRAP1 ablation improves mitochondrial cristae and oxidative phosphorylation in pancreatic cancer stem cells

CDK4/6 and BET inhibitors synergistically suppress pancreatic tumor growth and epithelial-to-mesenchymal transition by regulating the GSK3β-mediated Wnt/β-catenin pathway

Cryptotanshinone differentially induces cell death in ATP6V0D1-deficient pancreatic cancer cells

The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models

Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance

Discovery of the inhibitor of DNA binding 1 as a novel marker for radioresistance in pancreatic cancer using genome-wide RNA-seq

Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approach

SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance

Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer

The implication of liquid biopsies to predict chemoresistance in pancreatic cancer

Emerging RAS-directed therapies for cancer

The dark side of immunotherapy: pancreatic cancer

Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials